圣湘生物：公司四款产品取得医疗器械注册证

Core Viewpoint - Shengxiang Bio (688289.SH) has recently received medical device registration certificates from the National Medical Products Administration for four products, enhancing its capabilities in respiratory pathogen detection [1] Group 1: Product Details - The approved products include nucleic acid testing kits for respiratory syncytial virus, influenza A and B viruses, adenovirus, and mycoplasma pneumoniae, all utilizing fluorescent PCR methods [1] - These products enable unified sampling, amplification, and simultaneous detection of multiple common respiratory pathogens, supporting precise clinical medication and antibiotic management [1] Group 2: Market Impact - The future performance of these products post-approval is influenced by various factors, including market expansion efforts, brand influence, and actual market demand [1] - There is uncertainty regarding product sales and profit contributions due to these influencing factors [1]